IPO snapshot · 25 Sept 2026
Last verified 4 Oct 2026This page preserves the IPO terms and company information available at listing. Later share prices and financial results are not included.
- Valuation at IPO
- $1.8BBasic equity value after the offering
- Offer price at IPO
- $17.00Per share · USD
- Offering size
- $446.3MBase offering, before overallotment
- Listing date
- 25 Sept 2026First day of trading
Company overview
ADARx Pharmaceuticals websiteADARx Pharmaceuticals is a biotechnology company developing next-generation siRNA therapeutics. Its programs are at a late clinical stage and are designed to treat a broad spectrum of diseases.
- Company country
- United States
Offering details
USD · Base offering, before overallotment
- Exchange
- Nasdaq Global Select Market
- Ticker
- ADRX
- Shares offered
- 26,250,000
- Shares after offering
- 106,801,325
- New shares
- 26,250,000
- Existing shares sold
- 0
- Gross proceeds to company
- $446.3M
- Gross proceeds to shareholders
- $0
- Optional additional shares
- 3,937,500
Valuation and offering basis
Basic equity valuation is the price per share multiplied by all shares outstanding immediately after the offering. It is different from enterprise value or fully diluted valuation. Offering size and gross proceeds exclude optional additional shares, fees and expenses. Ranges use the proposed price range; figures are rounded.
IPO timeline
Filings and documents
- Listing announcementChecked 4 Oct 2026 (undated source)View document
- View document
- View document
- View document
Advisers
- Lead underwriter
- J.P. Morgan Securities LLC
- Lead underwriter
- Morgan Stanley & Co. LLC
- Lead underwriter
- TD Securities (USA) LLC
- Lead underwriter
- UBS Securities LLC
- Lead underwriter
- LifeSci Capital LLC